Apr.  7, 2005  45  US 2005/0074487 Al  TABLE  93  [0469]  The cumulative amount of enalapril maleate across  human cadaver skin at 24 hours increased from 0.029  mg/cm $^{2 }$to 1.826 mg/cm $^{2 }$when the calculated excess NaOH  concentration in the dried patch was increased from 1.9% to  6.9% as compared to undetectable flux for the formulation  without NaOH. The formulation of Enal-3 provided up to  63-fold more enalapril maleate flux than the formulation of  Enal-2.  [0470]  All patents, publications, and other published  documents mentioned or referred to in this specification are  herein incorporated by reference in their entirety.  [0471]  It is to be understood that while the invention has  been described in conjunction with the preferred specific  embodiments hereof, the foregoing description, as well as  the examples which are intended to illustrate and not limit  the scope of the invention, it should be understood by those  skilled in the art that various changes may be made and  equivalents may be substituted without departing from the  scope of the invention. Other aspects, advantages and modi› fications will be apparent to those skilled in the art to which  the invention pertains.  [0472]  Accordingly, the scope of the invention should  therefore be determined with reference to the appended  claims, along with the full range of equivalents to which  those claims are entitled.  We claim:  1. A  method for enhancing the flux of a drug selected from  the group consisting of antidepressant drugs, bone density  regulators, antihypertensive agents, drugs for the treatment  of Alzheimer’s disease, and antipsychotic agents, through a  body surface, comprising: administering the drug and a  pharmaceutically acceptable inorganic base to a localized  region of a human patient’s body surface; the base being  present in an amount effective to provide a  pH  within the  range of about 8.0-13.0 at the localized region of the body  surface during administration of the drug and effective to  enhance the flux of the drug through the body surface  relative to the flux that would be obtained in the absence of  the base, and without causing damage thereto; wherein the  drug and base are present in a formulation and the amount  of base in the formulation applied to the body surface is the  total of (a) the amount required to neutralize any acidic  species in the formulation plus (b) an amount equal to  approximately 0.3-25.0 wt % of the formulation.  2.  The method of claim 1, wherein the  pH  is within the  range of about 8.5-11.5.  3.  The method of claim 2, wherein the  pH  is within the  range of about 9.5-11.5.  4.  The method of claim 1, wherein the base is selected  from the group consisting of ammonium hydroxide, sodium  hydroxide, potassium hydroxide, calcium hydroxide, mag› nesium  hydroxide, magnesium oxide, calcium oxide,  sodium acetate, sodium borate, sodium metaborate, sodium  carbonate, sodium bicarbonate, sodium phosphate, potas› sium carbonate, potassium bicarbonate, potassium citrate,  potassium acetate, potassium phosphate, ammonium phos› phate, and combinations thereof.  5.  The method of claim 1, wherein the base is selected  from the group consisting of inorganic hydroxides, inorganic  oxides, inorganic salts of weak acids, and combinations  thereof.  6.  The method of claim 5, wherein the base is an inorganic  hydroxide.  7.  The method of claim 6, wherein the base is present in  an amount that is the total of (a) the amount required to  neutralize the acidic species plus (b) an amount equal to  about 0.3-7.0 wt % of the composition.  8.  The method of claim 6, wherein the inorganic hydrox› ide is selected from the group consisting of ammonium  hydroxide, alkali metal hydroxides, and alkaline earth metal  hydroxides.  9.  The method of claim 8, wherein the inorganic hydrox› ide is ammonium hydroxide.  10.  The method of claim 8, wherein the inorganic hydrox› ide is an alkali metal hydroxide selected from the group  consisting of sodium hydroxide and potassium hydroxide.  11.  The method of claim 8, wherein the inorganic hydrox› ide is an alkaline earth metal hydroxide selected from the  group consisting of calcium hydroxide and magnesium  hydroxide.  12.  The method of claim 5, wherein the base is an  inorganic oxide.  13.  The method of claim 12 wherein the base is present in  an amount that is the total of (a) the amount required to  neutralize the acidic species plus (b) an amount equal to  about 2-20 wt % of the composition.  14.  The method of claim 12, wherein the inorganic oxide  is selected from the group consisting of magnesium oxide  and calcium oxide.  15.  The method of claim 5, wherein the base is an  inorganic salt of a weak acid.  16.  The method of claim 15, wherein the base is present  in an amount that is the total of (a) the amount required to  neutralize the acidic species plus (b) an amount equal to  about 2-20 wt % of the composition.  17.  The method of claim 15, wherein the inorganic salt of  a weak acid is selected from the group consisting of ammo› nium phosphate, alkali metal salts of weak acids, and  alkaline earth metal salts of weak acids.  18.  The method of claim 17, wherein the inorganic salt of  a weak acid is ammonium phosphate.  19.  The method of claim 17, wherein the inorganic salt of  a weak acid is an alkali metal salt of a weak acid selected  from the group consisting of sodium acetate, sodium borate,  sodium metaborate, sodium carbonate, sodium bicarbonate,  sodium phosphate, potassium carbonate, potassium bicar› bonate, potassium citrate, potassium acetate, and potassium  phosphate.  20.  The method of claim 1, wherein the body surface is  skin.  21.  The method of claim 1, wherein the body surface is  mucosal tissue.  22.  The method of claim 1, wherein the drug is admin› istered by applying a drug delivery device to the localized  region of the patient’s body surface thereby forming a body  surface-delivery device interface, the device comprising a  Cumulative Amount of Enalapril Maleate (mg/cm 2 )  Time  5.25 hours  17.25 hours  23.75 hours  Enal-1  0  0  0  Enal-2  0.021  0.029  0.029  Enal-3  1.027  1.640  1.826 